Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
Cytokinetics (Nasdaq: CYTK) has announced its eighth annual Communications Grant Program, which will award five grants to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. The program aims to support communications, awareness building, and community engagement initiatives.
Applications for the 2025 grants are open until November 3rd, 2025, with winners to be announced in January 2026. Eligible organizations must be nonprofits or registered charities in the US, Canada, Europe, or UK. Previous recipients include the AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA, and Stichting Cardiomyopathie Onderzoek Nederland.
Cytokinetics (Nasdaq: CYTK) ha annunciato il suo ottavo programma annuale di grant per la comunicazione, che assegnerà cinque contributi a organizzazioni di advocacy per i pazienti focalizzate su la cardiomiopatia ipertrofica (HCM) e sulle comunità affette da scompenso cardiaco. Il programma punta a sostenere iniziative di comunicazione, sensibilizzazione e coinvolgimento della comunità.
Le candidature per i grant del 2025 sono aperte fino al 3 novembre 2025, con i vincitori annunciati a gennaio 2026. Le organizzazioni eleggibili devono essere non profit o enti di beneficenza registrati negli Stati Uniti, in Canada, in Europa o nel Regno Unito. Tra i destinatari precedenti figurano AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA e Stichting Cardiomyopathie Onderzoek Nederland.
Cytokinetics (Nasdaq: CYTK) ha anunciado su octavo Programa Anual de Subvenciones para Comunicaciones, que otorgará cinco subvenciones a organizaciones de defensa de pacientes centradas en la cardiomiopatía hipertrófica (HCM) y las comunidades de insuficiencia cardíaca. El programa busca apoyar iniciativas de comunicación, concienciación y participación comunitaria.
Las solicitudes para las subvenciones de 2025 están abiertas hasta el 3 de noviembre de 2025, y se anunciarán los ganadores en enero de 2026. Las organizaciones elegibles deben ser sin fines de lucro o entidades benéficas registradas en Estados Unidos, Canadá, Europa o Reino Unido. Entre los galardonados anteriores se encuentran AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA y Stichting Cardiomyopathie Onderzoek Nederland.
Cytokinetics (Nasdaq: CYTK)가 환자 옹호 단체를 대상으로 하는 비대해성 심근병증(HCM) 및 심부전 커뮤니티에 초점을 둔 8번째 연례 커뮤니케이션 보조금 프로그램을 발표했습니다. 이 프로그램은 커뮤니케이션, 인식 제고 및 커뮤니티 참여 이니셔티브를 지원하는 것을 목표로 합니다.
2025년 보조금 신청은 2025년 11월 3일까지이며, 수상자는 2026년 1월에 발표될 예정입니다. 자격 요건은 미국, 캐나다, 유럽 또는 영국에 등록된 비영리 조직 또는 자선단체이어야 합니다. 과거 수혜 기관으로는 AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA, Stichting Cardiomyopathie Onderzoek Nederland가 있습니다.
Cytokinetics (Nasdaq: CYTK) a annoncé son huitième Programme annuel de subventions pour la communication, qui attribuera cinq bourses à des organisations de défense des patients axées sur la cardiomyopathie hypertrophique (HCM) et les communautés souffrant d’insuffisance cardiaque. Le programme vise à soutenir les initiatives de communication, de sensibilisation et d’engagement communautaire.
Les candidatures pour les subventions 2025 sont ouvertes jusqu’au 3 novembre 2025, et les lauréats seront annoncés en janvier 2026. Les organisations éligibles doivent être des associations à but non lucratif ou des œuvres caritatives enregistrées aux États‑Unis, au Canada, en Europe ou au Royaume‑Uni. Parmi les bénéficiaires précédents figurent AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA et Stichting Cardiomyopathie Onderzoek Nederland.
Cytokinetics (Nasdaq: CYTK) hat ihr achtes jährliches Communications Grant Program angekündigt, das fünf Zuschüsse an Patientenvertretungsorganisationen verleiht, die sich auf hypertrophe Kardiomyopathie (HCM) und Herzinsuffizienz-Gemeinschaften konzentrieren. Das Programm zielt darauf ab, Kommunikations-, Aufklärungs- und Gemeinschaftsengagement-Initiativen zu unterstützen.
Die Bewerbungen für die Zuschüsse 2025 sind bis zum 3. November 2025 geöffnet, die Gewinner werden im Januar 2026 bekannt gegeben. Berechtigt sind gemeinnützige Organisationen oder registrierte Wohltätigkeitsorganisationen in den USA, Kanada, Europas oder dem Vereinigten Königreich. Frühere Empfänger sind u. a. AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA und Stichting Cardiomyopathie Onderzoek Nederland.
سيتيكوينيتيكس (ناسداك: CYTK) أعلنت عن البرنامج الثامن السنوي لمنح الاتصالات، الذي سيمنح خمس منح لمنظمات دعم المرضى التي تركز على اعتلال عضلة القلب التضخمي (HCM) ومجتمعات فشل القلب. يهدف البرنامج إلى دعم مبادرات الاتصالات، وزيادة الوعي، ومشاركة المجتمع.
التقديم لجوائز 2025 مفتوح حتى 3 نوفمبر 2025، وسيتم الإعلان عن الفائزين في يناير 2026. يجب أن تكون المنظمات المؤهلة غير ربحية أو جمعيات خيرية مسجلة في الولايات المتحدة أو كندا أو أوروبا أو المملكة المتحدة. من المستفيدين السابقين هي AICARM APS وHeartBrothers Foundation وHeartCharged Corporation وHCMA وStichting Cardiomyopathie Onderzoek Nederland.
Cytokinetics (纳斯达克代码：CYTK)宣布了其第八届年度沟通资助计划，该计划将向专注于肥厚型心肌病（HCM）及心力衰竭社区的患者倡导组织授予五笔资助。该计划旨在支持沟通、提高认知度以及社区参与等项目。
2025 年资助的申请将持续至2025 年 11 月 3 日，获奖者将于 2026 年 1 月公布。符合条件的组织必须是美国、加拿大、欧洲或英国注册的非营利或慈善机构。以往获奖者包括 AICARM APS、HeartBrothers Foundation、HeartCharged Corporation、HCMA 以及 Stichting Cardiomyopathie Onderzoek Nederland。
- None.
- None.
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Deadline for Applications is November 3rd, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities. The grants are intended to support increased communications, awareness building and community engagement.
“A persistent funding gap for patient advocacy organizations is in the area of communications. Without adequate resources, patients and caregivers may miss out on important resources and information, while organizations struggle to effectively engage their communities, donors and partners,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement. “Through our Communications Grant Program, now in its eighth year, we are proud to support innovative, high-impact initiatives that amplify patient voices, strengthen connections and broaden reach.”
The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant Program may help with programming or personnel, depending on each organization’s needs. The recipients of the 2025 Cytokinetics Communications Grants were the AICARM APS (Italian Association of Cardiomyopathies), HeartBrothers Foundation, HeartCharged Corporation, Hypertrophic Cardiomyopathy Association (HCMA) and Stichting Cardiomyopathie Onderzoek Nederland (Foundation Cardiomyopathy Research the Netherlands).
Eligible organizations must have nonprofit organization or registered charity status in the United States, Canada, Europe or United Kingdom and serve the patient communities in HCM or heart failure. Organizations applying for the grant are required to submit a proposal outlining communication activities that the funding would support and the potential impact of the funding. Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria. More details can be found at the application portal listed below. Recipients are responsible for providing an outcomes report to Cytokinetics to measure the impact and results of the funding at the end of the year. Applications may now be submitted at https://www.cybergrants.com/Cytokinetics/communications_grant. The deadline to apply is November 3, 2025, and the grant recipients will be announced in January 2026. For more information on the program, including eligibility guidelines, visit https://cytokinetics.com/responsibility/grants-and-giving/.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is the deadline for Cytokinetics (CYTK) 2025 Communications Grant Program applications?
Who is eligible to apply for the Cytokinetics Communications Grant Program 2025?
What are the requirements for Cytokinetics (CYTK) Communications Grant Program applications?
Who were the recipients of Cytokinetics 2025 Communications Grants?
What does the Cytokinetics Communications Grant Program fund?
